Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Viemed Healthcare (VMD) Research & Development (2019 - 2025)

Viemed Healthcare (VMD) has disclosed Research & Development for 6 consecutive years, with $598000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 25.53% year-over-year to $598000.0, compared with a TTM value of $3.0 million through Dec 2025, down 1.66%, and an annual FY2025 reading of $3.0 million, down 1.66% over the prior year.
  • Research & Development was $598000.0 for Q4 2025 at Viemed Healthcare, down from $775000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $847000.0 in Q2 2025 and bottomed at $339000.0 in Q1 2021.
  • Average Research & Development over 5 years is $683650.0, with a median of $697000.0 recorded in 2022.
  • The sharpest move saw Research & Development skyrocketed 137.04% in 2021, then dropped 25.53% in 2025.
  • Year by year, Research & Development stood at $612000.0 in 2021, then increased by 17.97% to $722000.0 in 2022, then decreased by 9.83% to $651000.0 in 2023, then increased by 23.35% to $803000.0 in 2024, then decreased by 25.53% to $598000.0 in 2025.
  • Business Quant data shows Research & Development for VMD at $598000.0 in Q4 2025, $775000.0 in Q3 2025, and $847000.0 in Q2 2025.